Clinical Trial Update: Ongericimab Injection Reducing Recurrence of Ischemic Stroke [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigates Ongericimab injection to reduce recurrence of ischemic stroke. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• ONgericimab

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Ischemic Cerebral Infarction | Phase 3 | Status: NOT_YET_RECRUITING